Recent reports of patients failing to respond to ivermectin, the standard drug for treating river blindness (onchocerciasis), have suggested the emergence of drug-resistant Onchocerca volvulus ...

The Food and Drug Administration (FDA) has approved moxidectin for the treatment of onchocerciasis (river blindness) due to Onchocerca volvulus in patients ≥12 years of age. Menu SECTIONS Home ...